Erythropoietin: The swinging pendulum

Howard S. Oster; Drorit Neumann; Michael Hoffman; Moshe Mittelman

doi:10.1016/j.leukres.2012.04.017

Erythropoietin: The swinging pendulum

Howard S. Oster, Drorit Neumann, Michael Hoffman, Moshe Mittelman

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

Erythropoiesis stimulating agents (ESAs) have been used widely for anemic patients, especially those on dialysis and with cancer. However, reports have suggested shorter survival in erythropoietin (EPO)-treated cancer patients. The purpose of this review is to summarize and evaluate critically the current information about ESA treatment and its possible association with mortality in cancer patients. The pendulum that initially swung in the direction of widespread ESA treatment, and then in the direction of no treatment, is swinging back toward a stable position. This review also provides tools to decide how and when to use ESAs safely, according to accepted guidelines.

Original language	English
Pages (from-to)	939-944
Number of pages	6
Journal	Leukemia Research
Volume	36
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2012.04.017
State	Published - Aug 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
Erythropoiesis stimulating agents (ESAs)
Erythropoietin
Mortality
Quality of life
Survival

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2012.04.017

Cite this

@article{2369c6126b4a40679d3ebcb2c2df49d6,

title = "Erythropoietin: The swinging pendulum",

abstract = "Erythropoiesis stimulating agents (ESAs) have been used widely for anemic patients, especially those on dialysis and with cancer. However, reports have suggested shorter survival in erythropoietin (EPO)-treated cancer patients. The purpose of this review is to summarize and evaluate critically the current information about ESA treatment and its possible association with mortality in cancer patients. The pendulum that initially swung in the direction of widespread ESA treatment, and then in the direction of no treatment, is swinging back toward a stable position. This review also provides tools to decide how and when to use ESAs safely, according to accepted guidelines.",

keywords = "Cancer, Erythropoiesis stimulating agents (ESAs), Erythropoietin, Mortality, Quality of life, Survival",

author = "Oster, \{Howard S.\} and Drorit Neumann and Michael Hoffman and Moshe Mittelman",

year = "2012",

month = aug,

doi = "10.1016/j.leukres.2012.04.017",

language = "الإنجليزيّة",

volume = "36",

pages = "939--944",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Erythropoietin

T2 - The swinging pendulum

AU - Oster, Howard S.

AU - Neumann, Drorit

AU - Hoffman, Michael

AU - Mittelman, Moshe

PY - 2012/8

Y1 - 2012/8

N2 - Erythropoiesis stimulating agents (ESAs) have been used widely for anemic patients, especially those on dialysis and with cancer. However, reports have suggested shorter survival in erythropoietin (EPO)-treated cancer patients. The purpose of this review is to summarize and evaluate critically the current information about ESA treatment and its possible association with mortality in cancer patients. The pendulum that initially swung in the direction of widespread ESA treatment, and then in the direction of no treatment, is swinging back toward a stable position. This review also provides tools to decide how and when to use ESAs safely, according to accepted guidelines.

AB - Erythropoiesis stimulating agents (ESAs) have been used widely for anemic patients, especially those on dialysis and with cancer. However, reports have suggested shorter survival in erythropoietin (EPO)-treated cancer patients. The purpose of this review is to summarize and evaluate critically the current information about ESA treatment and its possible association with mortality in cancer patients. The pendulum that initially swung in the direction of widespread ESA treatment, and then in the direction of no treatment, is swinging back toward a stable position. This review also provides tools to decide how and when to use ESAs safely, according to accepted guidelines.

KW - Cancer

KW - Erythropoiesis stimulating agents (ESAs)

KW - Erythropoietin

KW - Mortality

KW - Quality of life

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84862524935&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.04.017

DO - 10.1016/j.leukres.2012.04.017

M3 - مقالة مرجعية

SN - 0145-2126

VL - 36

SP - 939

EP - 944

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Erythropoietin: The swinging pendulum

Abstract

UN SDGs

Keywords

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this